Success Metrics

Active Trials
2(50%)

Phase Distribution

Ph phase_1
2
50%
Ph early_phase_1
2
50%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
2(50.0%)
Phase 1Safety & dosage
2(50.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Other(2)

Detailed Status

unknown2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 12 (50.0%)
Phase 12 (50.0%)

Trials by Status

unknown250%
recruiting250%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_1

Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas

NCT07319676
recruitingearly_phase_1

UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases

NCT07441525
unknownearly_phase_1

NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer

NCT05248048
unknownphase_1

Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL

NCT04846439

Clinical Trials (4)

Showing 4 of 4 trials
NCT07319676Phase 1

Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas

Recruiting
NCT07441525Early Phase 1

UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases

Recruiting
NCT05248048Early Phase 1

NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer

Unknown
NCT04846439Phase 1

Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL

Unknown

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4